Reduced Renal Ammoniagenesis in Primary Gout

1974 ◽  
pp. 401-405 ◽  
Author(s):  
Alexander B. Gutman ◽  
Ts’ai-Fan Yü
Keyword(s):  
Primary Gout

scholarly journals Effects of fenofibrate therapy on renal function in primary gout patients

Rheumatology ◽  
2021 ◽  
Author(s):  
Xinde Li ◽  
Wenyan Sun ◽  
Jie Lu ◽  
Yuwei He ◽  
Ying Chen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Treatment Period ◽  
Mixed Model ◽  
Interaction Analysis ◽  
Serum Urate ◽  
Factors Affecting ◽  
Primary Gout ◽  
Potential Risk Factors ◽  
Multivariable Regression ◽  
Risk Predictors

Abstract Objective To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients. Methods A total of 983 gout patients on fenofibrate treatment who visited the dedicated Gout Clinic at the Affiliated Hospital of Qingdao University between September 2016 and June 2020 were retrospectively enrolled from the electronic records system. Fenofibrate-associated nephrotoxicity was defined as an increase in serum creatinine (SCr) ≥0.3 mg/dl within 6 months of fenofibrate initiation. The change trend of SCr and uric acid levels during the treatment period were assessed by a generalised additive mixed model (GAMM). Multivariate analysis was performed for risk factors affecting elevated SCr. Results A total of 100 (10.2%) patients experienced an increase in SCr ≥0.3 mg/dl within 6 months after fenofibrate initiation. The median change of SCr in the whole cohort was 0.11 mg/dl [interquartile range (IQR) 0.03–0.20], whereas it was 0.36 (0.33–0.45) in the fenofibrate-associated nephrotoxicity group. In a multivariable regression model, chronic kidney disease (CKD) [odds ratio (OR) 2.39 (95% CI 1.48, 3.86)] and tophus [OR 2.29 (95% CI 1.39, 3.78)] were identified to be risk predictors, independent of measured covariates, of fenofibrate-associated nephrotoxicity. During the treatment period, although SCr temporarily increased, serum urate and triglyceride concentrations decreased using the interaction analysis of GAMM. Of those with fenofibrate withdrawal records, the SCr increase in 65% of patients was reversed after an average of 49 days off the drug. Conclusions This observational study implied that fenofibrate-associated nephrotoxicity occurs frequently in gout patients, especially in patients with tophi or CKD. The potential renal risks of fenofibrate usage in gout needs additional research.

The Prevalence of Nephrolithiasis in Patients with Primary Gout: A Cross-sectional Study Using Helical Computed Tomography

2009 ◽  
Vol 36 (9) ◽  
pp. 1958-1962 ◽  
Author(s):  
TORU SHIMIZU ◽  
HIROSHI HORI
Keyword(s):  
Computed Tomography ◽  
Confidence Interval ◽  
Laboratory Data ◽  
Helical Computed Tomography ◽  
Cross Sectional ◽  
Patients Âgés ◽  
Primary Gout ◽  
Stone Formers ◽  
Significant Difference ◽  
History Of

Objective.To investigate the prevalence of nephrolithiasis in gouty patients by computed tomography (CT) imaging and to compare it with the “prevalence” of urolithiasis calculated from histories of urinary tract calculus.Methods.The kidneys of 383 male patients with primary gout were examined using an unenhanced 2-row helical CT detector, imaging at 2 mm collimation and a helical pitch of 3. The urolithiasis history of the 383 patients was investigated by inquiry. Patients’ ages, body mass index, and laboratory data from a 1-hour clearance test were determined.Results.CT scans confirmed nephrolithiasis in 103 (26.9%, 95% confidence interval 22.5%–31.6%) of the 383 gouty patients, and history of urinary calculus was positive in 65 (17.0%, 95% confidence interval 13.4%–21.1%) of the 383. However, 64 (62%) of the 103 stone-formers identified by CT had no history of urolithiasis. There was a significant difference between the ages of the 103 stone-formers identified by CT and the 65 stone-formers identified from the history.Conclusion.The prevalence of nephrolithiasis obtained using CT was 26.9% in the 383 patients with primary gout. Our results imply that we cannot determine an accurate prevalence of urolithiasis from a patient’s history. Most of the “prevalence” reported in the past may not correspond to a statistically justifiable one, but instead to the “cumulative incidence” during the contraction period of gout. Thus, the prevalence of nephrolithiasis confirmed by a cross-sectional method and the “prevalence” of urolithiasis calculated from patients’ calculus histories should be clearly distinguished.

Hyperlipidemia in primary gout

Metabolism ◽  
1968 ◽  
Vol 17 (3) ◽  
pp. 289-299 ◽  
Author(s):  
Keith A. Barlow
Keyword(s):  
Primary Gout

Analysis of the Genotypes for Aldehyde Dehydrogenase 2 in Japanese Patients with Primary Gout

1995 ◽  
pp. 53-56 ◽  
Author(s):  
Hisashi Yamanaka ◽  
Naoyuki Kamatani ◽  
Masayuki Hakoda ◽  
Chihiro Terai ◽  
Ryuji Kawaguchi ◽  
...  
Keyword(s):  
Aldehyde Dehydrogenase ◽  
Japanese Patients ◽  
Aldehyde Dehydrogenase 2 ◽  
Primary Gout

scholarly journals Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout

Rheumatology ◽  
2006 ◽  
Vol 46 (2) ◽  
pp. 215-219 ◽  
Author(s):  
J. Vazquez-Mellado ◽  
A. L. Jimenez-Vaca ◽  
S. Cuevas-Covarrubias ◽  
V. Alvarado-Romano ◽  
G. Pozo-Molina ◽  
...  
Keyword(s):  
Molecular Analysis ◽  
Primary Gout

scholarly journals Primary gout affecting the sternoclavicular joint.

BMJ ◽  
1976 ◽  
Vol 1 (6004) ◽  
pp. 262-262 ◽  
Author(s):  
G R Sant ◽  
E Dias
Keyword(s):  
Sternoclavicular Joint ◽  
Primary Gout
Sign in / Sign up

Export Citation Format

Share Document